GlassScriptPhysician profile
Maggie Jane Croyle
NPI 1174294250
$4,865.82
in general payments reported to CMS, 2019-2025
45 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.67 · 2022: $68.77 · 2023: $18.35 · 2024: $2,161 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,339 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.51 |
| Education | $443.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $677.42 | 2024-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $416.98 | 2024-2025 | |
| Janssen Biotech, INC. | $390.92 | 2024-2025 | Tecvayli, Erleada, Rybrevant |
| Incyte Corporation | $270.37 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $198.67 | 2024-2025 | |
| Astellas Pharma US INC | $196.60 | 2024-2025 | Padcev |
| Lilly USA, LLC | $195.90 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Acrotech Biopharma INC. | $176.79 | 2024-2025 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $170.94 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $163.25 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.20 | 2022-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $117.06 | 2024-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $116.33 | 2025 | Imfinzi, Calquence |
| Genmab U.S., INC. | $116.31 | 2024-2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $107.14 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $104.84 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Ipsen Biopharmaceuticals, INC | $100.57 | 2024-2025 | Onivyde, Tazverik |
| Pharmaessentia USA Corporation | $97.85 | 2024-2025 | Besremi |
| Eisai INC. | $97.05 | 2024-2025 | |
| Geron Corporation | $79.46 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $74.86 | 2024-2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $72.70 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $70.41 | 2024-2025 | Fruzaqla, Ninlaro |
| Genentech USA, INC. | $69.60 | 2024-2025 | Itovebi, Tecentriq Hybreza, Polivy |
| Abbvie INC. | $65.33 | 2025 | |
| Exelixis INC. | $62.03 | 2025 | Cabometyx |
| Adc Therapeutics America, INC. | $54.03 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $48.92 | 2022 | |
| Stemline Therapeutics INC. | $42.14 | 2025 | Orserdu |
| Taiho Oncology, INC. | $35.21 | 2024-2025 | |
| Tolmar, INC. | $34.34 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $34.34 | 2025 | Rubraca |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.02 | 2021-2023 | Lifevest |
| Collegium Pharmaceutical, INC. | $30.80 | 2025 | Xtampza, Belbuca |
| Deciphera Pharmaceuticals INC. | $25.59 | 2024 | Qinlock, Tgct |
| Caris Mpi, INC. | $22.88 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $22.33 | 2025 | Xpovio |
| Genzyme Corporation | $20.67 | 2025 | |
| Beigene USA, INC. | $18.41 | 2025 | Tevimbra |
| Novocure INC. | $18.10 | 2025 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.68 | 2025 | |
| Kyowa Kirin, INC. | $17.02 | 2025 | |
| Array Biopharma INC | $16.45 | 2024 | Lorbrena, Xalkori, Mektovi |
| Syndax Pharmaceuticals, INC. | $15.73 | 2025 | Revuforj |
| Sumitomo Pharma America, INC. | $14.58 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Croyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.